Business Context and Reporting Period
This Form 8-K Current Report was filed by DaVita Inc. on February 4, 2011. The filing discloses the entry into a Material Definitive Agreement regarding the acquisition of DSI Renal, Inc. ("DSI"), a dialysis provider, by DaVita Inc.
Key Financial Metrics
The filing does not provide standard operating financial metrics such as revenue, profit, cash flow, margins, or debt levels for DaVita Inc. or DSI. The only specific financial figures disclosed relate to the proposed transaction:
- Merger Consideration: $689.2 million in cash (subject to certain adjustments).
- Termination Fee: $27.5 million payable by DaVita under certain termination circumstances.
Material Changes
The primary material change is the execution of an Agreement and Plan of Merger. Under this agreement, a wholly-owned subsidiary of DaVita ("Merger Sub") will merge with and into DSI, making DSI a wholly-owned subsidiary of DaVita. All outstanding DSI equity securities will be converted into the right to receive the cash consideration.
Guidance, Outlook, and Risks
Transaction Conditions: Completion of the Merger is subject to customary closing conditions, including:
- Approval by a majority of outstanding DSI shares.
- Clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
- Entry into a non-competition agreement by certain DSI stockholders and affiliates.
- Absence of a "Company Material Adverse Effect" occurring after the agreement date.
Timeline and Termination: The transaction must close on or before August 4, 2011, unless extended by DaVita by one additional month under certain circumstances. Either party may terminate if the transaction fails to close by this date due to reasons not caused by their breach.
Risk Disclosure: The filing explicitly states that representations and warranties in the Merger Agreement were made solely for the benefit of the parties and may have been qualified by confidential disclosure schedules. Investors are advised not to rely on these representations as characterizations of actual facts.
Investor Verification Checklist
- Verify the final closing date and whether the August 4, 2011 deadline was met or extended.
- Confirm receipt of regulatory clearance under the Hart-Scott-Rodino Act.
- Review the final allocation of the $689.2 million consideration to ensure adjustments were calculated correctly.
- Monitor for any "Company Material Adverse Effect" that could trigger termination.
- Check for the execution of required non-competition agreements by DSI stockholders.